Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Closed Good Friday 04-17 16:00:00 EDT

1.44

+0.04

+2.86%

盘后1.45

+0.01+0.69%

19:52 EDT

High1.53	Low1.41	Vol1.19M
Open1.42	D1 Closing1.40	Amplitude8.75%
Mkt Cap69.56M	Tradable Cap62.60M	Total Shares48.31M
T/O1.74M	T/O Rate2.74%	Tradable Shares43.48M
P/B0.48	ROE-17.19%	EPS-1.46
52wk High42.20	52wk Low1.15	P/E-0.98
Dividend0.00	Div.Yield0.00	ROA-57.18%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":1.44,"timestamp":1744920000000,"preClose":1.4,"halted":0,"volume":1191942,"hourTrading":{"tag":"盘后","latestPrice":1.4499,"preClose":1.44,"latestTime":"19:52 EDT","volume":17616,"amount":25416.6,"timestamp":1744933921000},"delay":0,"floatShares":43475193,"shares":48307896,"eps":-1.461998,"marketStatus":"Closed Good Friday","change":0.04,"latestTime":"04-17 16:00:00 EDT","open":1.42,"high":1.5325,"low":1.41,"amount":1739921.243283,"amplitude":0.0875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.461998,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.4,"preHourTrading":{"tag":"盘前","latestPrice":1.4001,"preClose":1.4,"latestTime":"09:28 EDT","volume":2770,"amount":3949.7792870000003,"timestamp":1744896505886},"postHourTrading":{"tag":"盘后","latestPrice":1.4499,"preClose":1.44,"latestTime":"19:52 EDT","volume":17616,"amount":25416.6,"timestamp":1744933921000},"volumeRatio":1.2081089772772093,"impliedVol":2.5175,"impliedVolPercentile":0.8884},"requestUrl":"/m/hq/s/SAVA","defaultTab":"news","newsList":[{"id":"2524146146","title":"Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2524146146","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524146146?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 21:35","pubTimestamp":1743514507,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Cassava Sciences, Inc.  lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.The RSI reading of 24.25 for SAVA is an indicat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/down-39-52-4-weeks-133507471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVA","BK4150","BK4585","RSI","BK4588","BK4547","SAVAW","BK4007"],"gpt_icon":1},{"id":"2524240539","title":"Is the Future Bleak for SAVA Stock Following Another Setback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524240539","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524240539?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 22:00","pubTimestamp":1743429600,"startTime":"0","endTime":"0","summary":"Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects.Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline candidate, simufilam, in mild-to-moderate Alzheimer’s disease  failed to achieve the prespecified co-primary endpoints.Treatment with the drug failed to achieve a significant reduction in cognitive and functional decline in AD patients when compared to placebo over 76 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study also failed to meet any pre-specified secondary and exploratory biomarker endpoint.The REFOCUS-ALZ study enrolled 1,125 AD patients, who were randomized equally to receive either a twice-daily oral dose of simufilam  or placebo for 76 weeks. The candidate, however, demonstrated an acceptable safety profile in the study.However, with only $128.6 million in cash and equivalents at the end of December 2024, it is not certain how far the company can fund its operations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/future-bleak-sava-stock-following-140000247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0203201768.USD","LU1917777945.USD","BK4532","LLY","LU0238689110.USD","LU1267930730.SGD","LU0109391861.USD","SAVA","LU0823416689.USD","LU1093756325.SGD","SG9999015978.USD","LU1061106388.HKD","IE00B1BXHZ80.USD","LU2602419157.SGD","LU1232071149.USD","LU1551013425.SGD","LU2461242641.AUD","LU1804176565.USD","BK4581","LU0109394709.USD","SG9999018857.SGD","SGXZ31699556.SGD","LU2023250504.SGD","LU0106261372.USD","BIIB","LU2324357040.USD","LU1720051108.HKD","SAVAW","LU0354030438.USD","LU1988902786.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","SG9999014906.USD","IE00B19Z9Z06.USD","LU1712237335.SGD","LU2552382215.SGD","LU1069344957.HKD","LU0889565916.HKD","LU1551013342.USD","LU0256863902.USD","LU1983299246.USD","LU2357305700.SGD","SG9999018865.SGD","IE0004445239.USD","LU2237443382.USD","LU2360106947.USD","LU1868836591.USD","BK4533","IE00BJJMRZ35.SGD","BK4588"],"gpt_icon":1},{"id":"2522376893","title":"Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522376893","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522376893?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 03:38","pubTimestamp":1743017884,"startTime":"0","endTime":"0","summary":"Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drugBy Jonathan Stempel NEW YORK, March 26 (Reuters) - The biotechnology company Cassava Sciences SAVA.O failed on Wednesday t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL2N3Q90Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4547","SAVA","BK4007","BK4585"],"gpt_icon":1},{"id":"2522880492","title":"SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880492","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880492?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:43","pubTimestamp":1742989380,"startTime":"0","endTime":"0","summary":"Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second late-stage study for Alzheimer’s disease . Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein.Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive and functional decline in AD patients when compared to placebo over 76 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study also failed to meet any pre-specified secondary and exploratory biomarker endpoints.The REFOCUS-ALZ study had enrolled 1,125 AD patients who were randomized equally to receive either a twice-daily, oral dose of simufilam  or placebo for 76 weeks. The candidate, however, demonstrated an acceptable safe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sava-stock-down-alzheimers-drug-114300226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989771016.USD","LU0096364046.USD","LU0466842654.USD","SAVAW","LU2461242641.AUD","SSI","LU1917777945.USD","BK4583","LU1839511570.USD","GILD","SG9999001176.USD","LU2112291526.USD","LU2360106947.USD","LU1093756168.USD","BK4007","LU0820561909.HKD","BK4566","SGXZ81514606.USD","LU2265009873.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0006306889.USD","LU1988902786.USD","BK4547","BIIB","LU1280957306.USD","SAVA","SG9999001176.SGD","SG9999015986.USD","IE00B1BXHZ80.USD","SG9999014914.USD","LLY","LU0640476718.USD","LU0094547139.USD","LU2106854487.HKD","SG9999017495.SGD","LU1057294990.SGD","IE00BK4W5M84.HKD","LU1291159041.SGD","LU0114720955.EUR","LU0203202063.USD","IE0004445239.USD","LU2491050071.SGD","SG9999013999.USD","IE00BJLML261.HKD","LU0198837287.USD","BK4581","LU1868837136.USD","LU1093756325.SGD","BK4532","SGXZ51526630.SGD"],"gpt_icon":0},{"id":"2522783839","title":"Equity Markets Close Higher, Weak Consumer Confidence Data Lifts Fed Easing Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2522783839","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522783839?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 04:34","pubTimestamp":1742934842,"startTime":"0","endTime":"0","summary":"US benchmark equity indexes closed higher Tuesday as markets reacted to the latest economic data and comments from a Federal Reserve governor.The Nasdaq Composite rose 0.5% to 18,271.9, while the S&P ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BLSP4239.USD","DXD","EQR","LU0965509010.AUD","NOC","LMT","LU1989772840.SGD","BK4534","US3Y.BOND","CRWD","LU1934455194.USD","UDOW","DJX","DDM","US30Y.BOND","PSQ","US2Y.BOND","MNQmain","US5Y.BOND","TQQQ","BK4550","SQQQ","BK4543","QLD","LU0266013472.USD","SDOW","DOG","BK4585","TSYW.SI","QQQ","LU1941712348.USD","US6M.BOND","US10Y.BOND","MRK","US12M.BOND",".DJI","IE00BZ9MQY76.HKD","BA","USJW.SI",".SPX","LU1923622614.USD","US7Y.BOND","NQmain","USAW.SI","SAVA",".IXIC","QID","LU0265550946.USD","NVIW.SI","LU1988902786.USD"],"gpt_icon":1},{"id":"2522188162","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2522188162","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522188162?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:57","pubTimestamp":1742929058,"startTime":"0","endTime":"0","summary":"Mural Oncology  said Tuesday it will stop the development of nemvaleukin alfa for platinum-resistant ovarian cancer as it believes a phase 3 trial of the drug combined with Merck's  Keytruda is \"highly unlikely to achieve success\" at the final analysis.Shares of Mural slumped 59% following an increase in intraday trading volume to over 3.52 million from a daily average of about 156,000.Cassava Sciences  said that topline results from its phase 3 REFOCUS-ALZ study of simufilam showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease.The biotech company said the results did not meet the co-primary, secondary, and exploratory biomarker endpoints.Shares sank 33%, with intraday trading volume rising to over 13.8 million versus a daily average of about 1.96 million.Price: 1.53, Change: -2.30, Percent Change: -60.05","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BLSP4452.SGD","LU1983299246.USD","BK4516","MURA","LU0965508806.USD","LU1023059063.AUD","LU0965509101.SGD","LU1934455194.USD","SG9999013999.USD","LU0058720904.USD","SG9999015341.SGD","LU1162221912.USD","LU1093756325.SGD","LU1291159041.SGD","LU1929549753.HKD","LU0106261372.USD","LU2361045086.USD","LU0006306889.USD","BK4007","LU0266013472.USD","BK4585","BK4588","LU1585245621.USD","IE00BLSP4239.USD","LU0265550359.USD","SG9999014575.USD","SG9999001176.SGD","BK4534","LU1989772923.USD","LU1035773651.USD","LU1116320901.HKD","BK4533","IE00BJT1NW94.SGD","LU2023250504.SGD","LU0265550946.USD","LU1069347547.HKD","LU2324357040.USD","SG9999001176.USD","LU1941712264.USD","LU1066053197.SGD","BK4550","MRK","LU1066051498.USD","LU1934455863.HKD","SAVA","LU0289739699.SGD","LU0208291251.USD","LU1699723380.USD","LU1093756168.USD","LU0238689110.USD"],"gpt_icon":0},{"id":"2522600493","title":"Cassava Sciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522600493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522600493?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:51","pubTimestamp":1742917860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SAVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 11:51 ET (15:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA"],"gpt_icon":0},{"id":"2522000870","title":"Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2522000870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522000870?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 22:15","pubTimestamp":1742912125,"startTime":"0","endTime":"0","summary":"Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Hold rating on Cassava Sciences (SAVA – Research Report). The associated price t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cassava-sciences-alzheimers-drug-trials-fall-short-neutral-rating-maintained-amid-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cassava-sciences-alzheimers-drug-trials-fall-short-neutral-rating-maintained-amid-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SAVA","BK4547","BK4588","BK4007"],"gpt_icon":0},{"id":"2522008555","title":"Cassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be Discontinued","url":"https://stock-news.laohu8.com/highlight/detail?id=2522008555","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522008555?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 22:15","pubTimestamp":1742912100,"startTime":"0","endTime":"0","summary":"Cassava Sciences' shares fell sharply Tuesday morning after the company said it would discontinue the development of its Alzheimer's treatment after recent trials didn't meet any of their objectives.Shares declined sharply, falling nearly 22% to $2.20.The clinical-stage biotechnology company said that the third phase of its Refocus-ALZ study of simufilam didn't meet any of the primary endpoints, nor any secondary and exploratory biomarker endpoints.Alzheimer's disease is a progressive brain disorder and is the leading cause of dementia. Symptoms include memory loss, decline in cognition and difficulty performing everyday tasks.The two primary endpoints for the study were to see a change in cognition and function after a 76-week period, comparing each dose of simufilam to a placebo dose.Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun preclinica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Cassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be Discontinued","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SAVA","BK4547","BK4585","BK4007"],"gpt_icon":1},{"id":"2522207478","title":"Cassava Sciences Shares Drop 21% After Co to Discontinue Development of Alzheimer's Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522207478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522207478?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 21:34","pubTimestamp":1742909687,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4585","BK4547","SAVA","BK4588"],"gpt_icon":0},{"id":"2522713660","title":"BUZZ-Cassava falls after stopping development of Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522713660","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522713660?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 21:17","pubTimestamp":1742908631,"startTime":"0","endTime":"0","summary":"BUZZ-Cassava falls after stopping development of Alzheimer's drug** Shares of drug developer Cassava Sciences SAVA.O fall 21.4% to $2.20 premarket** SAVA says it will discontinue the development of its experimental treatment, simufilam, for Alzheimer's disease, by the end of Q2** In trials, the drug failed to significantly reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, compared to placebo** In November, co said it would stop all trials of the drug** The drug has been at the center of scrutiny after a medical professor linked to its development was charged with fraud in June** Stock fell 89.4% since Nov 2024  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80UF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SAVA","BK4547","BK4007","BK4588"],"gpt_icon":0},{"id":"2522075061","title":"Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075061","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075061?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:56","pubTimestamp":1742907386,"startTime":"0","endTime":"0","summary":"Cassava Sciences  said Tuesday that topline results from its phase 3 REFOCUS-ALZ study of simufilam showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease.The biotech company said the results did not meet the co-primary, secondary, and exploratory biomarker endpoints.The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76 compared to placebo.Shares of Cassava Sciences were down 18% in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4547","SAVA","BK4007","BK4585"],"gpt_icon":0},{"id":"2522807347","title":"Cassava Sciences Shares Fall 14.3% Premarket After Co to Discontinue Development of Alzheimer's Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522807347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522807347?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:42","pubTimestamp":1742906540,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4007","BK4588","BK4547","SAVA"],"gpt_icon":0},{"id":"2522020236","title":"Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522020236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522020236?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:24","pubTimestamp":1742905488,"startTime":"0","endTime":"0","summary":"UPDATE 2-Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study Recasts paragraph 1, adds background on the company and drug throughout. March 25  - Cassava Sciences SAVA.O said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage study, sending shares of the company down 20% in early trading.The drug came under close watch after a medical professor linked to its development was charged with fraud last year. Neuroscientist Hoau-Yan Wang allegedly submitted false data to get millions of dollars in public funds for research into the drug.Late last year, the company had disclosed plans to stop all trials of the drug after it failed in the first late-stage study called ReThink-ALZ. The company said on Tuesday that it will phase out development programs of the drug by the end of the second quarter.Cassava and two of its former executives were also charged by the U.S. Securities and Exchange C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SAVA","BK4585","BK4588","BK4547"],"gpt_icon":0},{"id":"2522027308","title":"Cassava to discontinue development of Alzheimer's disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522027308","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522027308?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:08","pubTimestamp":1742904531,"startTime":"0","endTime":"0","summary":"Cassava to discontinue development of Alzheimer's disease drugMarch 25 (Reuters) - Cassava Sciences SAVA.O said on Tuesday it will discontinue the development of its drug for Alzheimer's disease. (Reporting by Sriparna Roy in Bengaluru; Editing by Savio D'Souza) ((Sriparna.Roy@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4585","SAVA","BK4547"],"gpt_icon":0},{"id":"2522022470","title":"Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022470?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:05","pubTimestamp":1742904305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q8055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4585","BK4588","SAVA","BK4007"],"gpt_icon":0},{"id":"2522022407","title":"Cassava Sciences Inc - Refocus-Alz Study Did Not Meet Primary, Secondary, or Exploratory Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022407?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:05","pubTimestamp":1742904305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q8055:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","SAVA","BK4007","BK4588","BK4547"],"gpt_icon":0},{"id":"2522022403","title":"Cassava Sciences Inc - to Discontinue Alzheimer's Program With Simufilam by End of Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022403?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:05","pubTimestamp":1742904305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q8055:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4007","BK4585","BK4588","SAVA"],"gpt_icon":0},{"id":"2522027846","title":"Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2522027846","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522027846?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:05","pubTimestamp":1742904300,"startTime":"0","endTime":"0","summary":"Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to dem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048697/8339/en/Cassava-Sciences-Reports-Topline-Phase-3-REFOCUS-ALZ-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4588","BK4007","BK4585","SAVA","SD","BK4547"],"gpt_icon":0},{"id":"2519784293","title":"Chinese Drug Administration Accepts Application of Centergate Technologies' Unit for Oxycodone Hydrochloride Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2519784293","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519784293?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 15:14","pubTimestamp":1741936498,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the application of Beijing Centergate Technologies Holding's  subsidiary, Beijing Huasu Pharmaceutical, to market extended-release oxycodone hydrochloride tablets, according to a Shenzhen Stock Exchange disclosure on Thursday.The drug is used for the treatment of severe pain that requires long-term, continuous use of opioids, and when substitution therapies are not adequate to relieve the pain, the Chinese biomedicine and healthcare company said.The company's shares closed 2% higher.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000931","SAVA","BK0028","BK0239","BK4585","BK4007","BK4588","BK4547","BK0178","BK0075"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":0.2101},{"period":"1month","weight":-0.4839},{"period":"3month","weight":-0.4764},{"period":"6month","weight":-0.9503},{"period":"1year","weight":-0.9323},{"period":"ytd","weight":-0.3898}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.56,"avgChangeRate":0.149543},{"month":2,"riseRate":0.44,"avgChangeRate":0.027406},{"month":3,"riseRate":0.44,"avgChangeRate":0.008402},{"month":4,"riseRate":0.56,"avgChangeRate":0.05655},{"month":5,"riseRate":0.416667,"avgChangeRate":0.028089},{"month":6,"riseRate":0.458333,"avgChangeRate":-0.016342},{"month":7,"riseRate":0.458333,"avgChangeRate":0.000768},{"month":8,"riseRate":0.48,"avgChangeRate":0.013502},{"month":9,"riseRate":0.6,"avgChangeRate":0.108222},{"month":10,"riseRate":0.4,"avgChangeRate":-0.045759},{"month":11,"riseRate":0.6,"avgChangeRate":-0.00953},{"month":12,"riseRate":0.36,"avgChangeRate":0.032425}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction